[Form 3] Denali Capital Acquisition Corp. Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Navani Annu, listed at a Palo Alto address and identified as a director of Semnur Pharmaceuticals, Inc. (SMNR), filed an initial Form 3 reporting no securities beneficially owned. The filing is signed by an attorney-in-fact and references Exhibit 24 (Power of Attorney). The statement indicates this is an individual filing by one reporting person and records the event date as 09/22/2025.
Navani Annu, con domicilio a Palo Alto e identificata come direttrice di Semnur Pharmaceuticals, Inc. (SMNR), ha presentato un primo Modulo 3 segnalando nessuna partecipazione di titoli detenuti beneficiariamente. La dichiarazione, firmata da un procuratore, fa riferimento all'Allegato 24 (Power of Attorney). L’atto indica che si tratta di una presentazione individuale da parte di un solo riportante e riporta la data dell’evento come 22/09/2025.
Navani Annu, con domicilio en Palo Alto e identificada como directora de Semnur Pharmaceuticals, Inc. (SMNR), presentó un Formulario 3 inicial reportando ninguna participación de valores de forma beneficiosa. La presentación está firmada por un mandatario y hace referencia al Anexo 24 (Poder General). La declaración indica que es una presentación individual de una única persona reportante y registra la fecha del evento como 22/09/2025.
팔로 alto에 주소를 두고 있는 Navani Annu는 Semnur Pharmaceuticals, Inc.(SMNR)의 이사로 확인되며, 초기 폼 3를 제출하여 실질적으로 소유한 증권이 없음을 보고했습니다. 이 제출은 대리인이 서명했고 첨부 자료 24 (Power of Attorney)를 참조합니다. 이 진술은 단독 보고자에 의한 개인 제출임을 나타내며 사건 날짜를 2025-09-22로 기록합니다.
Navani Annu, résidant à Palo Alto et désigné comme directrice de Semnur Pharmaceuticals, Inc. (SMNR), a déposé un premier Formulaire 3 indiquant aucun titre détenu de manière bénéficiaire. Le dépôt est signé par un mandataire et fait référence à l’Annexe 24 (Power of Attorney). La déclaration indique qu’il s’agit d’un dépôt individuel par une seule personne déclarante et retient la date de l’événement au 22/09/2025.
Navani Annu, wohnhaft in Palo Alto und als Direktorin von Semnur Pharmaceuticals, Inc. (SMNR) identifiziert, hat eine anfängliche Form 3 eingereicht, in der kein Wertpapier im Eigentum der Person angegeben ist. Die Einreichung ist von einem Bevollmächtigten unterzeichnet und verweist auf Anhang 24 (Power of Attorney). Die Erklärung besagt, dass dies eine individuelle Einreichung durch eine meldende Person ist und das Ereignisdatum mit 22.09.2025 vermerkt wird.
Navani Annu، المقيمة في Palo Alto والمعرّفة كمديرة لـ Semnur Pharmaceuticals, Inc. (SMNR)، قدمت النموذج 3 الأول مُبلَّغاً عن عدم امتلاك أي أوراق مالية تمتَّلكها المستفيدة. التقديم مُوقَّع من قبل وكيل قانوني ويرتبط بالملحق 24 (Power of Attorney). وتشير البيان إلى أن هذا تقدِيم فردي من قبل مُبلغ واحد وتُسجَّل تاريخ الحدث كـ 22/09/2025.
Navani Annu，居住在 Palo Alto，被列为 Semnur Pharmaceuticals, Inc. (SMNR) 的 董事，已提交初始的 Form 3，报告 未直接拥有证券。该申报由一名代理签署，并参考第 24 附件（Power of Attorney）。声明指这是由单一申报人进行的个人申报，事件日期记为 2025/09/22。
Positive
- None.
Negative
- None.
Insights
TL;DR: Initial director filing reports no beneficial ownership, signaling no immediate insider share exposure.
The Form 3 documents a director-level reporting person who, at the time of the required disclosure event, does not beneficially own any shares or derivative positions in Semnur Pharmaceuticals, Inc. This is a routine disclosure required under Section 16. The inclusion of Exhibit 24 indicates a Power of Attorney was used to file the form on the reporting person's behalf.
TL;DR: Compliance filing is procedural and neutral; no securities held reduces potential Section 16 reporting triggers.
The Form 3 appears complete for its purpose: identifying the reporting person, relationship to the issuer as a director, and stating that no securities are beneficially owned. Because no positions are reported, there are no immediate Section 16(b) short-swing profit implications. The signature by an attorney-in-fact and reference to a Power of Attorney are procedural details relevant to filing authority.
Navani Annu, con domicilio a Palo Alto e identificata come direttrice di Semnur Pharmaceuticals, Inc. (SMNR), ha presentato un primo Modulo 3 segnalando nessuna partecipazione di titoli detenuti beneficiariamente. La dichiarazione, firmata da un procuratore, fa riferimento all'Allegato 24 (Power of Attorney). L’atto indica che si tratta di una presentazione individuale da parte di un solo riportante e riporta la data dell’evento come 22/09/2025.
Navani Annu, con domicilio en Palo Alto e identificada como directora de Semnur Pharmaceuticals, Inc. (SMNR), presentó un Formulario 3 inicial reportando ninguna participación de valores de forma beneficiosa. La presentación está firmada por un mandatario y hace referencia al Anexo 24 (Poder General). La declaración indica que es una presentación individual de una única persona reportante y registra la fecha del evento como 22/09/2025.
팔로 alto에 주소를 두고 있는 Navani Annu는 Semnur Pharmaceuticals, Inc.(SMNR)의 이사로 확인되며, 초기 폼 3를 제출하여 실질적으로 소유한 증권이 없음을 보고했습니다. 이 제출은 대리인이 서명했고 첨부 자료 24 (Power of Attorney)를 참조합니다. 이 진술은 단독 보고자에 의한 개인 제출임을 나타내며 사건 날짜를 2025-09-22로 기록합니다.
Navani Annu, résidant à Palo Alto et désigné comme directrice de Semnur Pharmaceuticals, Inc. (SMNR), a déposé un premier Formulaire 3 indiquant aucun titre détenu de manière bénéficiaire. Le dépôt est signé par un mandataire et fait référence à l’Annexe 24 (Power of Attorney). La déclaration indique qu’il s’agit d’un dépôt individuel par une seule personne déclarante et retient la date de l’événement au 22/09/2025.
Navani Annu, wohnhaft in Palo Alto und als Direktorin von Semnur Pharmaceuticals, Inc. (SMNR) identifiziert, hat eine anfängliche Form 3 eingereicht, in der kein Wertpapier im Eigentum der Person angegeben ist. Die Einreichung ist von einem Bevollmächtigten unterzeichnet und verweist auf Anhang 24 (Power of Attorney). Die Erklärung besagt, dass dies eine individuelle Einreichung durch eine meldende Person ist und das Ereignisdatum mit 22.09.2025 vermerkt wird.
FAQ
Who filed the Form 3 for Semnur Pharmaceuticals (SMNR)?
The Form 3 was filed for Navani Annu, who is identified as a director of Semnur Pharmaceuticals, Inc.
Does the Form 3 report any securities owned by the reporting person for SMNR?
No. The filing explicitly states no securities are beneficially owned by the reporting person.
What is the date of the event requiring the Form 3 filing?
The date of the event requiring the statement is 09/22/2025.
Was the Form 3 filed by more than one reporting person?
No. The form indicates it was filed by one reporting person.
Is there any power of attorney noted on the Form 3?
Yes. The filing references Exhibit 24 - Power of Attorney and is signed by an attorney-in-fact.
DENALI CAPITAL ACQ CP A
OTC:DNQAF
DNQAF Rankings
DNQAF Latest SEC Filings
Sep 25, 2025
[Form 4] Scilex Holding Co Insider Trading Activity
Sep 25, 2025
[Form 4] Scilex Holding Co Insider Trading Activity